|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
EP2789630A1
(en)
*
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
SMT202400235T1
(it)
|
2014-08-04 |
2024-07-09 |
Hoffmann La Roche |
Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
HK1254836A1
(zh)
|
2015-10-30 |
2019-07-26 |
Nbe-Therapeutics Ag |
抗-ror1抗体
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
MX2018008926A
(es)
|
2016-01-20 |
2019-01-10 |
Scripps Research Inst |
Composiciones de anticuerpo contra ror1 y métodos relacionados.
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
|
JP7022123B2
(ja)
*
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に対する二重特異性抗体
|
|
SG11201909160WA
(en)
*
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
AU2018289581C1
(en)
|
2017-06-23 |
2025-01-30 |
VelosBio Inc. |
ROR1 antibody immunoconjugates
|
|
GB201710836D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
|
US20210139579A1
(en)
*
|
2017-07-20 |
2021-05-13 |
Nbe-Therapeutics Ag |
Multispecific antibody product that binds to different ror1 epitopes
|
|
EP3665193A1
(en)
|
2017-08-07 |
2020-06-17 |
NBE Therapeutics AG |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
|
CN107827984B
(zh)
*
|
2017-09-13 |
2021-03-16 |
张慧林 |
嵌合抗ROR1抗体Fab分子及其制备方法和应用
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
TWI829667B
(zh)
*
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
MA52212A
(fr)
|
2018-03-30 |
2021-02-17 |
Merus Nv |
Anticorps multivalent
|
|
WO2019200022A1
(en)
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
CN112384533A
(zh)
*
|
2018-04-18 |
2021-02-19 |
埃克塞里艾克西斯公司 |
抗-ror抗体构建体
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
US20210340273A1
(en)
*
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
WO2020254352A1
(en)
*
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
SG11202112491WA
(en)
*
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
KR20220148175A
(ko)
|
2020-01-29 |
2022-11-04 |
인히브릭스, 인크. |
Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
TWI907489B
(zh)
*
|
2020-08-24 |
2025-12-11 |
香港商岸邁生物科技（香港）有限公司 |
抗ｒｏｒ１抗體及相關雙特異性結合蛋白
|
|
EP3988568A1
(en)
*
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
AU2021411896B2
(en)
*
|
2020-12-29 |
2025-12-11 |
Samsung Biologics Co., Ltd. |
Bi- or multi-specific antibody
|
|
KR20230166075A
(ko)
*
|
2021-02-02 |
2023-12-06 |
누맙 세러퓨틱스 아게 |
Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
CN120897932A
(zh)
*
|
2023-02-23 |
2025-11-04 |
阿达纳特股份有限公司 |
抗cd3抗体及其使用方法
|